Capital Fund Management S.A. Immuno Gen, Inc. Transaction History

Capital Fund Management S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $2.91 Million - $7 Million	233,841 Added 364.56%	297,985 $8.84 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $903,788 - $1.27 Million	64,144 New	64,144 $1.02 Million
Q3 2020 Nov 13, 2020	SELL	$3.45 - $4.89 $211,384 - $299,615	-61,271 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$3.32 - $5.34 $203,419 - $327,187	61,271 New	61,271 $281,000
Q4 2018 Feb 13, 2019	SELL	$3.94 - $9.7 $396,773 - $976,828	-100,704 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $866,054 - $1.13 Million	100,704 New	100,704 $954,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.